Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

Erasca Inc (ERAS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Erasca's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.550 -0.150    -8.82%
29/07 - Closed. Currency in USD
After Hours
1.570
+0.020
+1.29%
23:13:05 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,010,346
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.530 - 1.720
Erasca 1.550 -0.150 -8.82%

Erasca Inc Company Profile

 
Get an in-depth profile of Erasca Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

126

Equity Type

ORD

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company’s products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Contact Information

Address 3115 Merryfield Row Suite 300
San Diego, 92121
United States
Phone 858 465 6511
Fax -

Top Executives

Name Age Since Title
Karen Cichowski - - Scientific Advisory Board Member
Pablo Rodriguez-Viciana - - Scientific Advisory Board Member
Kevan M. Shokat - - Scientific Advisory Board Member
Jonathan E. Lim 52 2018 Co-Founder, Chairman & CEO
Ryan B. Corcoran - - Scientific Advisory Board Member
George Daniel Demetri 67 - Scientific Advisory Board Member
Stephen C. Blacklow - - Scientific Advisory Board Member
Bruce D. Roth - - Member of Research, Development, & Commercial Advisory Board
James A. Bristol 78 2018 Lead Independent Director
Julie Hambleton 67 2021 Independent Director
Valerie Harding-Start 65 2019 Independent Director
Pratik S. Multani 58 2018 Independent Director
Alexander Whitman Casdin 57 2018 Independent Director
Michael D. Varney 67 2020 Chairman of Research & Development, Scientific Advisory Board Member and Director
John Lo - 2022 Senior Commercial Advisor & Member of Research, Development and Commercial Advisory Board
Jean I. Liu 57 2022 Independent Director
Gregory Cosma - - Member of Research, Development, & Commercial Advisory Board
Piro Lito - 2025 Member of Scientific Advisory Board
Jean-Michel Vernier 63 2025 Senior Chemistry Advisor & Member of Research, Development and Commercial Advisory Board
Rene Bernards 72 - Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ERAS Comments

Write your thoughts about Erasca Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email